Isaac Israel
CEO
Claimed by owner Purple Biotech
Former names: Kitov Pharmaceuticals
Tumor-immune Evasion and Drug Resistance Therapies
Public on TASE Jul, 2013
Public on NASDAQ Jul, 2015
Public on NASDAQ Jul, 2015
Purple Biotech
www.globenewswire.com
•
Dec 10, 2020
Kitov Announces Name Change to Purple Biotech Ltd.
www.globenewswire.com
•
Nov 9, 2020
Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb
www.globenewswire.com
•
Oct 27, 2020
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
www.globenewswire.com
•
Sep 8, 2020
Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
www.globenewswire.com
•
Sep 4, 2020
Kitov Pharma Receives Notice of Intention to Grant Two Patents in China Covering Company's Lead Oncology Assets, CM24 and NT219
www.globenewswire.com
•
Jul 8, 2020
Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody
www.globenewswire.com
•
Jun 23, 2020
Kitov Announces $35.0 Million Registered Direct Offering
www.globenewswire.com
•
May 22, 2020
Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients
www.globenewswire.com
•
May 20, 2020
Kitov Announces U.S. Commercial Launch of Consensi™
www.globenewswire.com
•
May 19, 2020
Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II
www.globenewswire.com
•
Apr 20, 2020
Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants
www.globenewswire.com
•
Mar 12, 2020
Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue Forecast
www.globenewswire.com
•
Feb 24, 2020
Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers
www.globenewswire.com
•
Feb 3, 2020
Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24
www.benzinga.com
•
Jan 24, 2020
Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors - Benzinga
www.globenewswire.com
•
Apr 12, 2019
Kitov Announces Key Milestone in FameWave Acquisition
www.globenewswire.com
•
Mar 14, 2019
Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company
en.globes.co.il
•
Jan 17, 2019
Kitov raises $6m after positive cancer drug data
www.globenewswire.com
•
Jan 15, 2019
New Data on Kitov's NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect
seekingalpha.com
•
Jan 7, 2019
Kitov Secures Consensi Commercial Deal With Coeptis (NASDAQ:KTOV)
www.globenewswire.com
•
Oct 11, 2018
Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer
en.globes.co.il
•
Jan 3, 2018
Kitov Pharmaceuticals soars on US distribution agreement
kitovpharma.investorroom.com
•
Oct 15, 2017
http://kitovpharma.investorroom.com/Kitov-Pharmaceuticals-Announces-Phase-III-IV-Clinical-Trial-for-KIT-302-Successfully-Meets-Primary-Endpoint-and-also-Demonstrates-Drug-Candidate-Improves-Renal-Function
www.prnewswire.com
•
Jul 11, 2017
Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering
www.prnewswire.com
•
Jan 13, 2017
Kitov Enters Immuno-Oncology Field Through Acquisition of TyrNovo
www.globes.co.il
•
Sep 29, 2016
Kitov Pharma jumps on osteoarthritis trial success
www.prnewswire.com
•
Aug 10, 2016
Kitov Announces Issuance of U.S. Patent Securing Long-Term Exclusivity for KIT-302 Ahead of New Drug Application to the FDA
www.globes.co.il
•
Jun 29, 2016
Kitov Pharmaceuticals secondary offering raises $12m
www.prnewswire.com
•
Nov 20, 2015
Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
www.globes.co.il
•
Nov 8, 2015
Kitov Pharmaceuticals files to raise $12.5m on Nasdaq
www.globes.co.il
•
Jun 12, 2012
XTL Bio buys Kitov Pharmaceuticals for up to $48m
About
Purple Biotech is a clinical-stage company that advances first-in-class therapies to overcome tumor-immune evasion and drug resistance. The companys goal is to create successful, long-lasting treatments for patients with hard-to-treat cancers.
Purple Biotechs oncology pipeline comprises two drugs: CM-24 and NT-219. CM-24 is a monoclonal antibody-blocking CEACAM1, a novel immune checkpoint that supports tumor-immune evasion and survival through multiple pathways. NT-219 is a potential first-in-class small-molecule bi-specific inhibitor of two key cancer resistance pathways: STAT3 and IRS1/2.
Prior to focusing on oncology, Purple Biotech developed Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. The drug was approved by the U.S. Food and Drug Administration for marketing in the United States in 2018. The company has also partnered to commercialize Consensi in China and South Korea.
In May 2020, Purple Biotech announced the commercial launch of Consensi in the U.S. by Burke Therapeutics, the marketing partner of its U.S. distributor, Coeptis Pharmaceuticals.
Purple Biotechs oncology pipeline comprises two drugs: CM-24 and NT-219. CM-24 is a monoclonal antibody-blocking CEACAM1, a novel immune checkpoint that supports tumor-immune evasion and survival through multiple pathways. NT-219 is a potential first-in-class small-molecule bi-specific inhibitor of two key cancer resistance pathways: STAT3 and IRS1/2.
Prior to focusing on oncology, Purple Biotech developed Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension. The drug was approved by the U.S. Food and Drug Administration for marketing in the United States in 2018. The company has also partnered to commercialize Consensi in China and South Korea.
In May 2020, Purple Biotech announced the commercial launch of Consensi in the U.S. by Burke Therapeutics, the marketing partner of its U.S. distributor, Coeptis Pharmaceuticals.
Primary Sector
Life Sciences & HealthTech
Products
Consensi, NT-219, CM-24
Geographic markets
Global
Funding
Total Funding
$99.5M
Market Cap
$43.52M
Last Funding
$35M
Funding Stage
Total Rounds
8
Investors
1
News
(31)
www.globenewswire.com
•
Dec 10, 2020
Kitov Announces Name Change to Purple Biotech Ltd.
www.globenewswire.com
•
Nov 9, 2020
Kitov Expands Planned Phase 1/2 Clinical Trial of CM24 in Non-Small Cell Lung Cancer with New Cohort to Evaluate CM24 in Patients with Pancreatic Cancer Conducted with Bristol Myers Squibb
www.globenewswire.com
•
Oct 27, 2020
Kitov Pharma Receives Notice of Allowance for a U.S. Patent Covering its Anti-Cancer Drug Candidate, NT219
www.globenewswire.com
•
Sep 8, 2020
Kitov Announces Dosing of First Patient in Phase 1/2 Clinical Trial of NT219 in Advanced Cancer Patients
www.globenewswire.com
•
Sep 4, 2020
Kitov Pharma Receives Notice of Intention to Grant Two Patents in China Covering Company's Lead Oncology Assets, CM24 and NT219
www.globenewswire.com
•
Jul 8, 2020
Kitov Pharma Receives Notice of Intention to Grant a European Patent Covering CM24, its anti-CEACAM1 Antibody
www.globenewswire.com
•
Jun 23, 2020
Kitov Announces $35.0 Million Registered Direct Offering
www.globenewswire.com
•
May 22, 2020
Kitov Announces U.S. FDA Acceptance of Investigational New Drug Application to Conduct Phase 1/2 Clinical Trial of NT219 in Multiple Types of Advanced Cancer Patients
www.globenewswire.com
•
May 20, 2020
Kitov Announces U.S. Commercial Launch of Consensi™
www.globenewswire.com
•
May 19, 2020
Kitov to Present Preclinical Data on NT219 at American Association of Cancer Research Virtual Annual Meeting II
www.globenewswire.com
•
Apr 20, 2020
Kitov Pharma Ltd. Announces Cash Proceeds of $6.5 Million from Exercise of Warrants
www.globenewswire.com
•
Mar 12, 2020
Kitov Pharma Provides Update on Planned U.S. Launch of Consensi™ and Provides Three-Year Revenue Forecast
www.globenewswire.com
•
Feb 24, 2020
Kitov Pharma Expands Planned NT-219 Clinical Program for Difficult to Treat Cancers
www.globenewswire.com
•
Feb 3, 2020
Kitov Pharma Receives Issue Notification for a U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24
www.benzinga.com
•
Jan 24, 2020
Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors - Benzinga
www.globenewswire.com
•
Apr 12, 2019
Kitov Announces Key Milestone in FameWave Acquisition
www.globenewswire.com
•
Mar 14, 2019
Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company
en.globes.co.il
•
Jan 17, 2019
Kitov raises $6m after positive cancer drug data
www.globenewswire.com
•
Jan 15, 2019
New Data on Kitov's NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect
seekingalpha.com
•
Jan 7, 2019
Kitov Secures Consensi Commercial Deal With Coeptis (NASDAQ:KTOV)
www.globenewswire.com
•
Oct 11, 2018
Kitov Appoints Gil Efron as Deputy Chief Executive Officer and Chief Financial Officer
en.globes.co.il
•
Jan 3, 2018
Kitov Pharmaceuticals soars on US distribution agreement
kitovpharma.investorroom.com
•
Oct 15, 2017
http://kitovpharma.investorroom.com/Kitov-Pharmaceuticals-Announces-Phase-III-IV-Clinical-Trial-for-KIT-302-Successfully-Meets-Primary-Endpoint-and-also-Demonstrates-Drug-Candidate-Improves-Renal-Function
www.prnewswire.com
•
Jul 11, 2017
Kitov Pharmaceuticals Announces Pricing of $3.5 Million Registered Direct Offering
www.prnewswire.com
•
Jan 13, 2017
Kitov Enters Immuno-Oncology Field Through Acquisition of TyrNovo
www.globes.co.il
•
Sep 29, 2016
Kitov Pharma jumps on osteoarthritis trial success
www.prnewswire.com
•
Aug 10, 2016
Kitov Announces Issuance of U.S. Patent Securing Long-Term Exclusivity for KIT-302 Ahead of New Drug Application to the FDA
www.globes.co.il
•
Jun 29, 2016
Kitov Pharmaceuticals secondary offering raises $12m
www.prnewswire.com
•
Nov 20, 2015
Kitov Pharmaceuticals Holdings Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
www.globes.co.il
•
Nov 8, 2015
Kitov Pharmaceuticals files to raise $12.5m on Nasdaq
www.globes.co.il
•
Jun 12, 2012
XTL Bio buys Kitov Pharmaceuticals for up to $48m
The Team
(6)
II
GE
Gil Efron
Deputy CEO & CFO
HRP
Hadas Reuveni, PhD
Co-founder & VP R&D
LF
Lior Fhima
CFO
BL
Bertrand Liang
CMO
MS
Michael Schickler
Head of Clinical & Regularly Affairs
Connect with
What is the reason for connecting?
Your company *
Your position *
Add invitation message
0/300
Sending invitation...
Company Lifecycle
Public Offerings & Exits
Initial Public Offering
EXIT
$10M
Jul 2013
Stock Exchange
TASE
Valuation
Undisclosed
$10M
Public Offering
$13M
Jul 2015
Stock Exchange
NASDAQ
Valuation
Undisclosed
$13M
Private Equity Funding
Undisclosed Round
$10M
Jan 2012
1 Investors
$10M
Post-IPO Equity Funding
$13M
Oct 2015
$13M
Post-IPO Equity Funding
$6M
Jan 2019
$6M
Post-IPO Equity Funding
$6M
Mar 2020
$6M
Post-IPO Equity Funding
$6.5M
Apr 2020
$6.5M
Post-IPO Equity Funding
$35M
Jun 2020
$35M
Media gallery
(0)Locations
Israel
Rehovot, Israel
Locations
Israel
Rehovot, Israel
Unlock financial data
Finder is provided for free by the non-profit organization Start-Up Nation Central.
- Get unlimited search results
- Save to custom lists - Smartlists
- Get notified with news and updates
- Connect with people
And much more...
I already have access,